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Background: Samples collected from CF patient airways often contain large amounts of host-derived nucleic acids that interfere with recovery and
puriﬁcation of microbial and viral nucleic acids. This study describes metagenomic and metatranscriptomic methods that address these issues.
Methods: Microbial and viral metagenomes, and microbial metatranscriptomes, were successfully prepared from sputum samples from ﬁve adult
CF patients.
Results: Contaminating host DNA was dramatically reduced in the metagenomes. Each CF patient presented a unique microbiome; in some
Pseudomonas aeruginosa was replaced by other opportunistic bacteria. Even though the taxonomic composition of the microbiomes is very
different, the metabolic potentials encoded by the community are very similar. The viral communities were dominated by phages that infect major
CF pathogens. The metatranscriptomes reveal differential expression of encoded metabolic potential with changing health status.
Conclusions: Microbial and viral metagenomics combined with microbial transcriptomics characterize the dynamic polymicrobial communities
found in CF airways, revealing both the taxa present and their current metabolic activities. These approaches can facilitate the development of
individualized treatment plans and novel therapeutic approaches.
© 2012 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Cystic ﬁbrosis; Viruses; Microbes; Metagenomics; Metatranscriptomics1. Introduction
In the lungs of cystic fibrosis (CF) patients, the defective
cystic fibrosis transmembrane regulator (CFTR) protein affects
transepithelial ion transport, consequently hindering the normal
airway clearance mechanisms [1,2]. The resultant static mucoid⁎ Corresponding author. Tel.: +1 619 594 1336; fax: +1 619 594 5676.
E-mail address: ylim@rohan.sdsu.edu (Y.W. Lim).
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http://dx.doi.org/10.1016/j.jcf.2012.07.009environment is colonized by a dynamic and complex commu-
nity of microbes, viruses, and fungi (reviewed in LiPuma et al.
[3]).
While standard microbial culture techniques had identified the
key pathogens, more recent culture-independent approaches based
on 16S rRNA gene sequencing revealed a much wider range of
microbial species associated with CF lungs [4–9]. However, 16S
rRNA-based methods are limited in taxonomic resolution and are
subject to biases (summarized in Claesson et al. [10]); theirby Elsevier B.V. All rights reserved.
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functions known for the taxa, thus overlooking potentially
important strain-specific variants. Metagenomics can overcome
those limitations.
The metagenomic approach has been used to study viruses
in human-associated environments such as blood [11], feces
[12–14], and the lungs [15]. It has also been successfully used
to characterize the viral communities in sputum samples from
CF and non-CF individuals [15]. The presence of phages in CF
airways is of particular relevance for clinical treatment, as
environmental stress from the CF mucus and frequent antibiotic
treatment is known to enhance phage mobility and promote the
phage-mediated spread of antibiotic resistance genes in CF
lungs [16,17].
On the other hand, it is challenging to generate microbial
metagenomes from CF samples. One reason for this is that
microbial DNA isolated from CF sputum or lung tissue samples
usually contains a large amount of human DNA, often greater
than 99% of the total DNA recovered [18–20]. Although some
intact human cells may be present in the original sample, most
of the contaminating DNA is extracellular and adsorbed to the
surface of microbes, making isolation of pure microbial DNA
particularly difficult.
Complementing metagenomics, metatranscriptomics charac-
terizes the microbial genes expressed in an environment and can
monitor shifts in their transcription or stability in response to
perturbations, e.g., antibiotic treatments in CF patients. This
approach has been used to investigate microbial community
metabolism inmarine [21–23] and soil [24,25] environments, but
its application to host-associated microbes has been limited to a
few instances [26,27] due to technical challenges (Supplementary
Table 1). One such challenge is that messenger RNAs (mRNAs)
account for only ~5% of total cellular RNA. Various rRNA
depletion methods have been developed to enrich samples for
mRNA (Supplementary Table 2). Concurrent application of
multiple methods (e.g., mRNA-ONLY™, MICROBExpress™
and MessageAmp™) can remove more of the rRNA in some
instances, but efficacy remains limited, especially when working
with partially degraded rRNA [28].
Metatranscriptomics of host-associated communities is
particularly difficult. Amplification of the microbial RNA by
methods that utilize synthetic polyadenylation is not applicable
for samples that contain large amounts of eukaryotic mRNA.
The appended poly-A tails reduce the amount of useful
sequence data, especially when pyrosequencing technologies
such as Roche/454 [29] are used. Due to the short half-life and
small quantity of mRNA, sample filtration and manipulation
with buffer should be avoided prior to RNA extraction. This
inevitably causes an increase in host RNA contamination when
dealing with host-associated microbial samples. In the recent
microbial metatranscriptomic study of mule deer lymph nodes
by Wittekindt et al. [26], 99.3% of the taxonomically assigned
reads were host-derived and b0.01% were microbial.
Here we describe protocols to generate viral and microbial
metagenomes, as well as microbial metatranscriptomes, from
fresh CF sputum using 454 GS FLX Titanium pyrosequencing
(Fig. 1). These methods target and enrich for viral and microbialDNA, as well as microbial mRNA, while minimizing contam-
ination with host nucleic acids. This is the first study to
simultaneously survey the microbiome, virome, and community
metatranscriptome in any ecosystem.
2. Materials and methods
Note: A detailed standard protocol describing each step can
be downloaded from www.coralandphage.org.
2.1. Sample collection
Eight sputum samples were collected from five CF volunteers
(CF1 through CF5) at the Adult CF Clinic (San Diego, CA, USA)
by expectoration into a sterile cup, with the exception of sample
CF4-A that was a tracheal aspirate. All collection was in
accordance with the University of California Institutional Review
Board (HRPP 081500) and San Diego State University
Institutional Review Board (SDSU IRB#2121). Clinical status at
the time of collection was designated as exacerbation (prior to
systemic antibiotic treatment), on treatment (during systemic
antibiotic treatment), post treatment (upon completion of antibiotic
treatment) or stable (when clinically stable and at their clinical and
physiological baseline). Each sample was syringe-homogenized
and divided into aliquots for metagenomic and metatranscriptomic
analyses, culturing, and storage.
2.2. Virome protocol
(Supplementary Note 1) Dithiothreitol was added to the
diluted sputum to aid mucus dissolution. Viral particles were
purified by cesium chloride (CsCl) density gradient ultracen-
trifugation as described in Thurber et al. [30]. For one sample
(CF4-A), the density gradient purification step was omitted for
comparison. Viral DNA was extracted using CTAB/phenol:
chloroform, and amplified with Phi29 DNA polymerase.
2.3. Microbiome protocol
(Supplementary Note 1) Sputum samples were treated with
β-mercaptoethanol to disrupt mucus. Pelleted bacterial cells
were repeatedly washed and centrifuged, then treated with
DNase to remove human DNA.
2.4. Microbial metatranscriptome protocol
(Supplementary Note 1) Microbial cells in the sputum
aliquots were mechanically lysed by vortexing with zirconia
beads in TRIzol® LS (Life Technologies, NY, USA). RNA was
extracted using the Zymo Clean & Concentrator™ 25 kit
(Zymo Research, Irvine, CA, USA) with the small RNA
removal protocol variation and treated with RNase-free DNase
I (Ambion, Life Technologies: Grant Island, NY, USA).
cDNA was generated using the WTA-2 kit (Sigma-Aldrich).
The effect of nebulization on transcript length was assessed as
described in Supplementary Note 2. Similarly, two rRNA
depletion methods were tested: (i) the ‘Ambion’ method, i.e.,
Viral DNA Microbial RNAMicrobial DNA
- MercaptoethanolPre-treatment
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enrichment of 
viral/microbial
cells
Nucleic acid
extraction
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Hypotonic lysis of 
eukaryotic cells
Silica column-based2
3
Dithiothreitol
Low speed 
centrifugation
0.45 m
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ultracentrifugation
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Formamide/CTAB Trizol LS coupled 
with column-based 
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rRNA & human RNA 
removal4
Whole Transcriptome
5
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in Trizol LS1
1
 Trizol LS, a more concentrated form of Trizol reagent, was used for liquid samples.
2
 The silica column-based NucleoSpin Tissue Kit (Machery-Nagel, Düren, Germany) with the Grampositive protocol.
3
 Amplification by phi29 DNA polymerase.
4
 Removal of microbial and human rRNA by the Epicentre Ribo-ZeroTM Meta Kit.
5
 TransPlexTM Complete Whole-Transcriptome Amplification (WTA2) kit (Sigma-Aldrich: St. Louis, MO).
Fig. 1. Workflow for the preparation of CF sputum samples for microbiome, virome, and metatranscriptome sequencing.
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bacterial rRNA as well as human rRNA and mRNA; and
(ii) the Ribo-Zero™ method, i.e., Ribo-Zero™ rRNA Removal
kit (Epidemiology version) (Epicentre, an Illumina company,
Madison, WI) that removes bacterial and human rRNA.
2.5. Sequencing and data preprocessing/analysis
All samples were sequenced using the GS-FLX Titanium
chemistry system. Primer tags in WTA amplified samples were
removed using TagCleaner [31]. All datasets were preprocessed
to remove duplicates and reads of low quality using PRINSEQ
[32] (Supplementary Note 1). Metagenomic datasets were
further screened and human-derived reads were removed using
DeconSeq [33].
The preprocessed metagenomes were annotated using
BLASTn against the NCBI nucleotide database. Sequences
assigned to the phylum Chordata and to vector or synthetic
sequences were identified and removed. Virome sequences
were then compared against an in-house boutique viral database
containing 4019 unique complete viral genomes using tBLASTx
and normalized viral abundances were calculated. In the pre-
processed metatranscriptomes, rRNA-like and non-rRNA reads
were identified using BLASTn against the SILVA database [34].Non-rRNA reads were annotated using BLASTx against the
NCBI non-redundant protein database. For details of database
generation and content, normalization, as well as BLAST pa-
rameters, see Supplementary Note 1.
2.6. Taxonomic assignments
The best hit was assigned to the alignment with the highest
coverage, identity, and score values. Query sequences with no
BLAST hits above the defined threshold were designated as
unassigned. The diversity of microbiomes was calculated based
on the number of bacterial species identified in the datasets
(Supplementary Note 1).
2.7. Metabolic pathways
Sequences from the metagenomes and metatranscriptomes
(excluding all Chordata, vector, and synthetic sequences) were
compared against the KEGG protein database using BLASTx.
(The CF1-A metatranscriptome was omitted due to insufficient
data.) For each pathway, the best hits and their abundances
were identified and normalized using HUMAnN [35]. Normal-
ized pathway abundance values were used to calculate
similarities between samples based on random forests [36]
157Y.W. Lim et al. / Journal of Cystic Fibrosis 12 (2013) 154–164and to partition the samples by Partitioning Around Medoids
(PAM) clustering [37].2.8. Data accessibility
Sequence data was deposited in the NCBI Short Read Archive
(SRA) with accession numbers SRP007749, SRP009392, and
SRP009438.3. Results and discussion
This is the first study to describe a comprehensive workflow
(Fig. 1) for the generation of viromes, microbiomes, and
microbial metatranscriptomes from any environment. The cou-
pling of metagenomic and metatranscriptomic approaches pro-
vides an overview of both who is there and what they are doing,
i.e., community taxonomy combined with the community's en-
coded and expressed functional diversity. For this work, viral
metagenomes (viromes), microbial metagenomes (microbiomes),
and microbial metatranscriptomes were generated from twelveTable 1
Results summary for all viromes, microbiomes, and metatranscriptomes.
Patient ID Time point Date of collection Health status Metagenomes
Microbial
% microbial se
(number of mic
CF1 A 09/02/2010 Stable N/A c
B 10/18/2010 Stable N/A c
C 11/12/2010 On treatment N/A c
D 02/11/2011 Exacerbation 9%
(14,691)
E 02/24/2011 On treatment 58%
(67,780)
F 03/14/2011 Post treatment 79%
(40,825)
CF2 A 11/10/2010 On treatment N/A c
CF3 A 11/10/2010 On treatment N/A c
CF4 A 01/22/2011 Exacerbation 2%
(3834)
B 02/01/2011 Post treatment 0.2%
(405)
C 03/20/2011 Stable 23%
(41,636)
CF5 A 10/07/2011 Exacerbation 2%
(1034)
B 10/21/2011 Post treatment 1%
(247)
a Based on tBLASTx against viral genome database (threshold of 40% identity ov
b Observation by epifluorescence microscopy of the viral fraction collected follow
c Sample not available.
d Following rRNA depletion by the Ambion kits.
e Following rRNA depletion by the Ribo-Zero™ (Epidemiology) kit.
f Sample collected by filtration through 0.45 μm filter without cesium chloride defresh sputum samples that had been collected from five adult CF
patients (Table 1).
3.1. Viruses in CF sputum
The metagenomic approach was successfully used previ-
ously to characterize viruses in CF lungs [15]. In this study,
viromes were generated from eight sputum samples obtained
from three CF patients (Table 1, Supplementary Table 3). Two
methods for purifying virus-like particles (VLPs) from sputum
were compared. Seven samples were purified by filtration and
cesium chloride density gradient ultracentrifugation, followed
by chloroform and DNase I treatment. This procedure yielded
viromes that contained little (0.02%–3.7%) host-derived
sequence (with one exception due possibly to its exceptionally
high amount of mucins and free DNA, thus more viscous
sputum; Supplementary Table 3). Omission of the density
gradient ultracentrifugation step for the eighth sample
(see Materials and methods) resulted in a virome with 97%
host-derived sequence. Cesium chloride density gradient
centrifugation, previously shown to recover the majority ofMetatranscriptomes
Viral Microbial
quences
robial sequences)
% viral sequences a
VLPs observed b
% non-rRNA sequences
(number of non-rRNA sequences)
N/A c 10.7% d
(738)
N/A c 30.3% d
(41,789)
N/A c 30.6% d
(38,532)
6.59%
Yes
95.4% e
(1900)
31.99%
Yes
N/A c
6.07%
No
31.6% e
(7971)
N/A c 87.6% d
(68,976)
N/A c 89.6% d
(93,375)
0.90% f
No
86.8% d
(59,394)
6.77%
No
99.1% e
(32,446)
1.93%
No
95.1% e
(34,411)
3.00%
Yes
N/A c
3.78%
Yes
N/A c
er at least 60% of the query sequence).
ing cesium chloride density gradient centrifugation.
nsity gradient ultracentrifugation.
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ing host contamination when isolating viruses from complex
samples such as CF sputum.
Analysis of the seven cesium chloride density-purified
viromes using tBLASTx against the viral genome database
identified more than 450 viral genotypes with each virome
containing 319–456 genotypes (except CF4-C that contained
only eight; Fig. 2a). Unknowns accounted for 49% to N99% of
the total reads in most of the viromes (Supplementary Table 3),
which is typical for viral metagenomes [15]. The exceptions
were those samples highly contaminated by host sequences
(CF4-A and CF4-C; Fig. 2a). The high number of “unknown”
sequences implies the presence of novel viruses that cannot be
identified by database similarity, as had been found in previous
studies [11,15].b
c
a Patient CF1
Time Point D E F A*
Health Status Exacerbation On Treatment
Post 
Treatment Exacerbation
% Host 
Contamination 0.21% 0.71% 0.04% 97.27%
% Unknown 94.97% 82.16% 48.87% 2.36%
Total Viral Hits 
(tBLASTx) 7,214 (7%) 23,550 (32%) 4,070 (6%) 737 (0.9%)
Total Phage 
genotypes 329 319 348 110
Top 21 putative host ran
* CF4-A: Without cesium chloride ultracentrifugation
** Mainly Streptococcus phage Dp-1
Enterococcus
Stenotrophomonas
Staphylococcus 
Bacillus 
Rhizobium 
Bordetella 
Thermus 
Gordonia 
Actinoplanes 
Archaea 
Escherichia 
Tsukamurella 
Aeromonas
Ralstonia 
Haloarcula 
Burkholderia 
Streptomyces 
Enterobacteria 
Pseudomonas 
Mycobacterium 
Streptococcus 
Other 
0.1 10 1000 0.1 10 1000 0.1 10 1000 0.1 10 100
**
Fig. 2. Taxonomic analysis of CF viromes. (a) Putative host range profiles for phage
for all phage genotypes with the same putative bacterial host. Only the top 21 hosts a
region of the Streptococcus phage Dp-1 genome. Depth of coverage was based on 90%
alignment quality. (c) Coverage plot of Acinetobacter sp. SUN resistance plasmid pThe majority of the viruses identified were phage, pre-
dominantly those that infect known CF pathogens. Their
predicted bacterial hosts were tallied and the top 21 were used
to construct predicted host range profiles (Fig. 2a). The profiles
were highly similar between patients, and even more so for
multiple samples from the same patient. They were dominated by
phages that infect major CF pathogens such as Streptococcus,
Burkholderia,Mycobacterium,Enterobacteria, andPseudomonas
genera. Streptococcus phage (particularly Dp-1) were found
in high abundance in the samples with the greatest abun-
dance (N30%) of Streptococcus spp. (i.e., CF1-D and CF1-E;
Fig. 4a).
Streptococcus phage Dp-1 had been first isolated in 1975
from patients presenting with upper respiratory symptoms and
was described as a virulent phage [38]. Here tBLASTx analysisCF4 CF5
B C A B
Post 
Treatment Stable Exacerbation
Post 
Treatment
0.02% 70.10% 0.27% 3.70%
99.74% 27.35% 48.94% 75.46%
4,642 (7%) 22 (2%) 6,466 (3%) 5,981 (4%)
302 8 456 422
ge for phage communities
0 0.1 10 1000 0.1 10 1000 0.1 10 1000 0.1 10 1000
communities. Each bar represents the sum of the normalized abundance values
re shown. (b) Nucleotide-level alignment of CF1-E virome sequences against a
nucleotide identity. The colors represent different nucleotides and demonstrate
RAY recovered from CF1-E and CF5-A.
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host-receptor recognition, tail and capsid structural proteins,
and host lysis (endolysin). The endolysin suggests possible
top-down control of the Streptococcus spp. by lytic phage
predation in these patients [39].
When reads from the CF1-E virome were mapped against
the Dp-1 reference genome (GI:327198314), high depth of
coverage was observed for a Dp-1 genome fragment in a 3 kbp
region that codes for an antireceptor and a minor structural
protein (Fig. 2b). Similarly, high coverage of regions of the
Acinetobacter sp. SUN resistance plasmid pRAY was also
observed in three samples (CF1-E, CF5-A, and CF5-B),
including regions encoding a domain of the Abi-2 superfamily
(proteins that confer resistance to phage infection) and
mobilization proteins (Fig. 2c). Finding these short sequences
from these two genomes highly enriched in the viromes implies
that they must be present in many other genomes, as well, likely
the result of active horizontal gene transfer (HGT) in CF lungs.
HGT is an important mechanism by which microbes evolve and
adapt to the CF lung environment [40], and phage can
potentially facilitate this process.
The archaeal virus BJ1 (GI: 119756985) was identified in
every virome — the first finding of an archaeal virus in the
lungs. The hypersaline surface liquid in CF airways may be
ecologically similar to the hypersaline lake in Inner Mongolia
where the virus was isolated [41]. Archaea were identified in
low abundance in one microbiome (CF4-C; b0.1%) and all
metatranscriptomes (b1%; data not shown), suggesting that
they could play a role in the CF lung ecosystem. However,
since more than 71% of the predicted ORFs for this archaeal
virus show no similarity to any known genes, its genome
sequence provides no clues as to what that role might be.
Eukaryotic DNA viruses in CF individuals have been shown
to be dominated by a few viral genomes [15] that could
potentially cause persistent infections, exacerbations, tumori-
genesis, and poor clinical outcomes [42–44]. The eukaryotic
viruses identified in a previous study of the lungs of CF patients
included torque teno virus (TTV), retroviruses, and human
herpesviruses [15]. In the current study, eukaryotic viruses,
including human herpesviruses and retroviruses, were found in
all samples (Supplementary Table 4), with torque teno viruses
in high abundance in one sample (CF1-D).
Because RNA viruses are involved in the majority of
respiratory infections, a filtration-based method was used to
isolate RNA viruses from CF sputum (data not shown).
However, this method was unable to recover identifiable
RNA viruses, likely due their low abundances and technical
challenges in their isolation.
3.2. Microbes in CF sputum
When characterizing a microbial community, metagenomics
surpasses a 16S rRNA-based approach in that it [1] frequently
permits high-confidence species-level taxonomic assignment;
[2] allows prediction of specialized functional capabilities of
the adapted community, rather than inferring function from
taxonomy; and [3] avoids the bias inherent in the selection ofany universal target for PCR amplification. However, pre-
parations of ‘microbial’ DNA derived from CF sputum or lung
tissue are typically dominated by human DNA that was
extracellular or adsorbed to the microbes. Several standard
methods, including separation of human and microbial cells by
percoll gradients [45], treatment with DNase I, selective
degradation of human DNA by ethidium bromide monoazide
[46], and use of the MolYsis kit (Molzym Life Science), have
failed to reduce human DNA in CF samples (personal
communications). In this study, the most effective procedure
was found to be a modification of the method described by
Breitenstein et al. [18] that employs a combination of
β-mercaptoethanol to reduce biofilm disulfide bonds, hypoton-
ic lysis of eukaryotic cells, and DNase I treatment of soluble
DNA (Supplementary Fig. 1; Supplementary Table 5). Suffi-
cient microbial DNA was extracted by this procedure to make
amplification prior to sequencing unnecessary, thus avoiding
potential amplification bias.
The amount of human contamination (13%–97% of total
preprocessed reads) was highly dependent on the sample
properties. Samples collected from patients during exacerba-
tions might be expected to contain higher levels of host DNA
due to greater inflammation and neutrophil activity than those
collected during and immediately following treatment. How-
ever, our metagenomic data showed no significant correlation
between the fraction of host DNA and a patient's health status
even though the amount of host DNA varies markedly among
the metagenomes.
With high-throughput pyrosequencing, even a relatively
small proportion of non-host sequence data can be sufficient to
provide significant information. After the removal of eukary-
otic reads, the microbiomes contained N75% bacterial reads
(Table 1) and 2%–12% unknowns, with the remainder being
artificial and cloning vectors or synthetic constructs (Supple-
mentary Table 5). The number of bacterial species identified,
including aerobes and anaerobes, ranged from 24 to 256
(Supplementary Table 6).
Each patient presented a unique microbial profile (Fig. 3a).
The predominant groups persisted across the time points
assayed but the relative abundance varied with exacerbations
and antibiotic treatments. This suggests complex community
dynamics in which the predominant groups adapt and persist,
while others come and go in response to antibiotic treatment or
other perturbations.
CF4 presented a classic CF lung microbiome where P.
aeruginosa was one of the main players at all time points. In
contrast, CF1 was colonized mainly by Rothia mucilaginosa and
Streptococcus spp. during exacerbation. Effective treatments
decreased R. mucilaginosa, thereby increasing the proportion of
P. aeruginosa. The Rothia dentocariosa that colonized CF5
during exacerbations was eliminated by treatments, and the
patient was subsequently colonized by Pseudomonas fluores-
cence instead of the common CF pathogen, P. aeruginosa. The
microbiome profiles also showed that P. aeruginosa can be
replaced as the main player by other opportunistic bacteria from
the environment, as evidenced here by the colonization of
(i) CF5, a landscape architect, by soil-dwelling P. fluorescens
b c
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Fig. 3. Taxonomic analysis of the microbial communities in three CF patients across multiple time points. (a) Species-level comparisons between microbiomes.
Identification was based on unique best hits using BLASTn against the NCBI nucleotide database. All species shown from the same genus are assigned similar
colors. (b) Sequence coverage of the Rothia mucilaginosa DY-18 genome by reads from the CF1-E microbiome. (c) Genus-level comparisons between
microbiomes and metatranscriptomes. (The CF4-A taxonomy is not shown here because an rRNA removal kit was used during metatranscriptome preparation.)
160 Y.W. Lim et al. / Journal of Cystic Fibrosis 12 (2013) 154–164instead of the more common CF pathogen, P. aeruginosa, and
(ii) CF1 by the oral flora R. mucilaginosa (Fig. 3a). By going
beyond the traditional tracking of particular recognized CF
pathogens, metagenomics offers the possibility of personalized
clinical treatment plans.
In some situations, metagenomics can yield in-depth
genomic analysis [47,48]. In this study, the CF1-E microbiome
provided 7.8× average coverage over 93.56% of the genome of
the most abundant species, R. mucilaginosa. Mapping of short
reads against the reference genome DY-18 (GI: 283133067)
(Fig. 3b) revealed only 41 gaps that were N1000 bp. Of those
gaps, almost 20% were located in non-coding regions, 20% in
regions annotated as hypothetical proteins, and the rest in genesof known function (Supplementary Table 7). In-depth analysis
and interpretation of the genomic changes will be presented
elsewhere (manuscript in preparation).
3.3. Evaluation of microbial metatranscriptome preparation
A high quality metatranscriptome contains relatively few
rRNA reads and an unbiased sampling of RNAs of various
lengths. Nebulization, the first step during preparation of a
sequencing library, is a potential source of transcript size-
induced bias since the size of our cDNA ranged from 50 to
4000 bp (Supplementary Fig. 2). While nebulization of high
molecular weight DNA creates random fragments, application
161Y.W. Lim et al. / Journal of Cystic Fibrosis 12 (2013) 154–164to lower molecular weight cDNA may result in non-uniform
coverage or the loss of short transcripts [49].
Here, the effect of nebulization on transcript length was
tested on four samples (Supplementary Note 1). There was no
difference in the relative translated protein length profiles with
and without nebulization (Supplementary Fig. 3). The median
translated polypeptide length (345–412 amino acids; Supple-
mentary Table 8) is in the high range of previously described
microbial protein lengths [50], possibly due to the use of the
small RNA removal protocol in the RNA Clean & Concentrator™
kit (Zymo).
Nebulization also did not affect the relative proportion of
rRNA-like and non-rRNA reads, although the proportion of
rRNA varied from patient to patient (9.4% to 70.8%; Fig. 4a).
A reduced rRNA fraction was often associated with an
increased proportion of eukaryote and unidentified reads.
Effective mRNA enrichment by rRNA removal using sub-
tractive hybridization (e.g., theMICROBEnrich™ fromAmbion)
had been previously demonstrated on synthetic microbial com-
munities [28]. However, efficacy depended on the integrity of
the RNA and community composition. Here, four samples
(CF1-D, CF1-F, CF4-B, and CF4-C) were used to compare two
hybridization-based commercial rRNA removal kits. Each sample
was divided into three aliquots for alternative treatments: (A)
MICROBEnrich™+MICROBExpress™ (Ambion); (E) Earlya
b
Fig. 4. Evaluation of the effects of nebulization and rRNA depletion on the rela
nebulization. All samples were treated by the Ambion rRNA depletion kits. (b) Com
MICROBEnrich™+MICROBExpress™; “Epicentre” method uses Ribo-Zero™ raccess version of Ribo-Zero™ rRNA removal kit - Epidemiology
(Epicentre); and (N) No treatment. In total, these twelve
metatranscriptomes yielded 425,523 reads (105 Mbp), 48 – 77%
of which were retained after data preprocessing (average read
length=252 bp).
With either treatment, the proportion of rRNA was reduced
significantly for CF1-D but minimally for CF1-F (Fig. 4b,
Supplementary Table 9). Of the two treatment methods, the
Ribo-Zero™ is more effective in eukaryotic rRNA removal as
evidenced by CF4-B and CF4-C. In these samples that contained
a larger proportion of eukaryotic reads, the Ribo-Zero™ treat-
ment removed 96% and 90% of the rRNA, while the Ambion
treatments increased the relative rRNA content.
Notably these rRNA removal methods were markedly less
effective for sample CF1-F. Even with Ribo-Zero™, the most
effective for all other samples, the treatment yielded only a 5%
reduction in total rRNA. This inter-sample variation in rRNA
removal could reflect differences in the microbial community
present, the quality of extracted RNA, the accessibility of rRNAs
for probe hybridization, and/or the degree of homology between
the designed rRNAprobes and the unknown communitymembers.
Use of either rRNA depletion treatment precludes subse-
quent rRNA-based analysis of the sample because both
methods distort the apparent relative abundances of microbial
taxa (Supplementary Fig. 4). Bias was apparent for all samplestive amounts of rRNA and non-rRNA in metatranscriptomes. (a) Effects of
parison of rRNA depletion methods. “Ambion” method uses a combination of
RNA Removal kit (Epidemiology version).
162 Y.W. Lim et al. / Journal of Cystic Fibrosis 12 (2013) 154–164except CF1-F; neither rRNA depletion method had significant
effect on that sample.
3.4. Microbial taxonomy three ways
Three methods were used to determine the relative abun-
dances of the microbial genera present within a patient sample:
[1] annotation of microbiomes; [2] 16S rRNA-based annotation
of metatranscriptomes; and [3] annotation of metatranscriptomes
based on encoded protein sequences. The marked differences
observed among the three (Fig. 3c) indicate that some community
members are more transcriptionally active, thus contribute more
to community metabolism than their relative numbers would
predict. This is further evidenced by functional characterization
(see below).
3.5. Community metabolic profiles
Whereas metagenomics surveys the functional capabilities
encoded by members of the microbial commmunity, adding
metatranscriptomic data provides insights into the current
metabolic activities, insights that can assist in tailoring an
effective treatment. To compare these approaches, the viromes,
microbiomes, and metatranscriptomes were functionally anno-
tated using the Kyoto Encyclopedia of Genes and Genomes
(KEGG) database. A total of 216 metabolic pathways and 212
modules (collection of functional units) were identified. Multi-
dimensional scaling (MDS) and clustering of all datasets based
on the normalized abundance value (see Materials and methods)Fig. 5. Comparison of KEGG metabolic pathways identified in viromes,
microbiomes, and metatranscriptomes as shown by multidimensional scaling
(MDS). Grouping by Partitioning Around Medoids (PAM) clustering placed
all samples in the appropriate cluster with the exception of the CF4-C
metatranscriptome. CF1-A was omitted from both analyses due to insufficient
data.yielded three distinct groups, thus showing that a different view
of community metabolism can be obtained from each method
(Fig. 5). The results demonstrate the internal consistency of each
method. The few exceptions were (i) the clustering of the CF4-C
metatranscriptome with the microbiomes; (ii) the clustering of the
CF4-B and CF5-B microbiomes with the metatranscriptomes
attributable to the low number of reads; (iii) the CF4-A virome,
purified without the gradient utracentrifugation, appearing as an
outlier in the virome cluster.
Overall, the metabolic profiles derived from the microbiomes
were the most similar between patients as well as between time
points for each patient (Supplementary Fig. 5), indicating a
shared pool of metabolic genes required for survival in the CF
environment. The greatest variation, likely reflecting specialized
adaptations within the viral and microbial communities, is seen in
the principal component analysis (PCA) plot (Supplementary
Fig. 6).
3.6. Clinical implications
The picture of dynamic and diverse polymicrobial communi-
ties presented here deviates from classic CF clinical profiles
derived from culturing, thereby challenging one-size-fits-all
treatment regimes. For example, current treatments targeting the
classic CF pathogen, P. aeruginosa, would not be effective
against P. fluorescence, R. mucilaginosa, or R. dentocariosa —
all of which were abundant in these microbiomes. The ability to
identify the resident viruses and microbes that could potentially
trigger exacerbation events makes effective individual treatment
plans a possibility, including intervention based on predicted
disease progression. Ongoing surveillance can monitor inter-
patient transmission and inform infection control measures. In
addition, shifting the focus from pathogen taxonomy to the
community metabolisms associated with periods of stability
and exacerbation opens the door to novel therapeutic approaches
that change the airway environment to favor less pathogenic
communities.
3.7. Summary
The combination of metagenomic and metatranscriptomic
approaches demonstrated here can provide insight into the
complex and dynamic interations between the host and both the
microbial and viral communities present in CF lungs.
• The methods described successfully recover viral DNA,
microbial DNA, and microbial mRNA from CF sputum,
while minimizing contamination with host nucleic acids.
• Of the viruses identified in the virome reads, most are phage
that infect major CF pathogens. These likely include vectors for
clinically-significant microbe-microbe horizontal gene transfer.
However, the majority of virome reads are “unknown,” thus
potentially novel viruses.
• To identify the microbes present, the microbiomes were
annotated using BLASTn against the NCBI nucleotide
database. Each CF patient possessed a unique microbial
profile that shifted over time and sometimes reflected the
163Y.W. Lim et al. / Journal of Cystic Fibrosis 12 (2013) 154–164acquisition of persistent opportunistic bacteria from the
environment. High genome coverage for the most abundant
species allowed in-depth genomic analysis.
• The third concurrent approach, microbial metatranscriptomics,
monitors the active community metabolism, as opposed to the
metabolic potential encoded in the genomes. Of the three
measures, the metatranscriptomes showed the greatest varia-
tion between patients and over time, thus is best able to capture
the dynamic nature of these complex communities.Acknowledgements
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